Study finds potential therapeutic target for pediatric acute myeloid leukemia

Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML.